J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal

Johnson & Johnson announced its acquisition of Intra-Cellular Therapies for $14.6 billion, its biggest deal in 2 years. The purchase will boost J&J’s presence in the brain disease treatment market. The deal includes Intra-Cellular’s oral therapy Caplyta, which brought in $481.3 million in sales in 2024. J&J plans to fund the transaction with cash and […]